Genetic factors in chronic inflammation: Single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn's disease in a New Zealand population

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 690, Issue 1-2, 2010, Pages 108-115

  Ferguson, Lynnette R ^a,c   Han, Dug Yeo ^a,c   Fraser, Alan G ^a,c   Huebner, Claudia ^a,c   Lam, Wen Jiun ^a,c   Morgan, Angharad R ^a,c   Duan, He ^b   Karunasinghe, Nishi ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c Nutrigenomics New Zealand   (New Zealand)

Author keywords

Crohn's disease; Genetics; Inflammatory bowel diseases; Janus kinases; Signal Transducers and Activators of Transcription; Signal transduction

Indexed keywords

JANUS KINASE; JANUS KINASE 2; STAT PROTEIN; STAT3 PROTEIN;

ADOLESCENT; ADULT; ALLELE; ARTICLE; BONE MARROW TUMOR; CAUCASIAN; COMET ASSAY; CONTROLLED STUDY; CROHN DISEASE; DNA DAMAGE; GENE FREQUENCY; GENE INTERACTION; GENE LOCATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOMIC INSTABILITY; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NEW ZEALAND; NUCLEOTIDE SEQUENCE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CROHN DISEASE; DNA DAMAGE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOMIC INSTABILITY; HUMANS; INFANT; JANUS KINASE 2; MALE; NEW ZEALAND; NOD2 SIGNALING ADAPTOR PROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 77954415692     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2010.01.017     Document Type: Article

References (31)

1. Loftus E.V. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004, 126:1504-1517.
2. Gearry R.B., Richardson A., Frampton C.M., Collett J.A., Burt M.J., Chapman B.A., Barclay M.L. High incidence of Crohn's disease in Canterbury, New Zealand: results of an epidemiologic study. Inflamm. Bowel Dis. 2006, 12:936-943.
3. Petermann I., Triggs C.M., Huebner C., Han D.Y., Gearry R.B., Barclay M.L., Demmers P.S., McCulloch A., Ferguson L.R. Mushroom intolerance: a novel diet-gene interaction in Crohn's disease. Br. J. Nutr. 2009, 102:506-508.
4. Han D.Y., Fraser A.G., Dryland P., Ferguson L.R. Environmental factors in the development of chronic inflammation: a case-control study on risk factors for Crohn's Disease within New Zealand. Mutat. Res. 2009.
5. Barrett J.C., Hansoul S., Nicolae D.L., Cho J.H., Duerr R.H., Rioux J.D., Brant S.R., Silverberg M.S., Taylor K.D., Barmada M.M., Bitton A., Dassopoulos T., Datta L.W., Green T., Griffiths A.M., Kistner E.O., Murtha M.T., Regueiro M.D., Rotter J.I., Schumm L.P., Steinhart A.H., Targan S.R., Xavier R.J., Libioulle C., Sandor C., Lathrop M., Belaiche J., Dewit O., Gut I., Heath S., Laukens D., Mni M., Rutgeerts P., Van Gossum A., Zelenika D., Franchimont D., Hugot J.P., de Vos M., Vermeire S., Louis E., Cardon L.R., Anderson C.A., Drummond H., Nimmo E., Ahmad T., Prescott N.J., Onnie C.M., Fisher S.A., Marchini J., Ghori J., Bumpstead S., Gwilliam R., Tremelling M., Deloukas P., Mansfield J., Jewell D., Satsangi J., Mathew C.G., Parkes M., Georges M., Daly M.J. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet. 2008, 40:955-962.
6. Anderson C.A., Massey D.C., Barrett J.C., Prescott N.J., Tremelling M., Fisher S.A., Gwilliam R., Jacob J., Nimmo E.R., Drummond H., Lees C.W., Onnie C.M., Hanson C., Blaszczyk K., Ravindrarajah R., Hunt S., Varma D., Hammond N., Lewis G., Attlesey H., Watkins N., Ouwehand W., Strachan D., McArdle W., Lewis C.M., Lobo A., Sanderson J., Jewell D.P., Deloukas P., Mansfield J.C., Mathew C.G., Satsangi J., Parkes M. Investigation of Crohn's disease risk loci in ulcerative colitis further defines their molecular relationship. Gastroenterology 2009, 136(523-529):e523.
7. Franke A., Balschun T., Karlsen T.H., Hedderich J., May S., Lu T., Schuldt D., Nikolaus S., Rosenstiel P., Krawczak M., Schreiber S. Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis. Nat. Genet. 2008, 40:713-715.
8. Wang K., Zhang H., Kugathasan S., Annese V., Bradfield J.P., Russell R.K., Sleiman P.M., Imielinski M., Glessner J., Hou C., Wilson D.C., Walters T., Kim C., Frackelton E.C., Lionetti P., Barabino A., Van Limbergen J., Guthery S., Denson L., Piccoli D., Li M., Dubinsky M., Silverberg M., Griffiths A., Grant S.F., Satsangi J., Baldassano R., Hakonarson H. Diverse genome-wide association studies associate the IL12/IL23 pathway with Crohn Disease. Am. J. Hum. Genet. 2009, 84:399-405.
9. Ferguson L.R., Shelling A.N., Browning B.L., Huebner C., Petermann I. Genes, diet and inflammatory bowel disease. Mutat. Res. 2007, 622:70-83.
10. Levine R.L., Pardanani A., Tefferi A., Gilliland D.G. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat. Rev. Cancer 2007, 7:673-683.
11. Jones A.V., Chase A., Silver R.T., Oscier D., Zoi K., Wang Y.L., Cario H., Pahl H.L., Collins A., Reiter A., Grand F., Cross N.C. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat. Genet. 2009, 41:446-449.
12. Vannucchi A.M. JAK2: how many faces in MPDs?. Blood 2008, 111.
13. Campbell P.J. Somatic and germline genetics at the JAK2 locus. Nat. Genet. 2009, 41:385-386.
14. Singh N.P., McCoy M.T., Tice R.R., Schneider E.L. A simple technique for quantisation of low levels of DNA damage in individual cells. Exp. Cell Res. 1988, 175:184-191.
15. Dusinska M., Collins A.R. The comet assay in human biomonitoring: gene environment interactions. Mutagenesis 2008, 23:191-205.
16. Jurinke C., van der Boom D., Cantor C.R. The use of MassARRAY technology for high throughput genotyping. Adv. Biochem. Eng. Biotechnol. 2002, 77:57-74.
17. Storm N., Darnhofer-Patel B., van den Boom D., Rodi C.P. MALDI-TOF mass spectrometry-based SNP genotyping. Methods Mol. Biol. 2003, 212:241-262.
18. Karunasinghe N., Ryan J., Tuckey J., Masters J., Jamieson M., Clarke L.C., Marshall J.R., Ferguson L.R. DNA stability and serum selenium levels in a high-risk group for prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2004, 13:391-397.
19. Gedik C.M., Boyle S.P., Wood S.G., Vaughan N.J., Collins A.R. Oxidative stress in humans: validation of biomarkers of DNA damage. Carcinogenesis 2002, 23:1441-1446.
20. Sasieni P.D. From genotypes to genes: doubling the sample size. Biometrics 1997, 53:1253-1261.
21. Wigginton J.E., Cutler D.J., Abecasis G.R. A note on exact tests of Hardy-Weinberg equilibrium. Am. J. Hum. Genet. 2005, 76:887-893.
22. Ihaka R.A.R., Gentleman R. A language for data analysis and graphics. J. Comput. Graph. Stat. 1996, 299-314.
23. Hampe J.J., Franke A., Rosenstiel P., Till A., Teuber M., Huse K., Albrecht M., Mayr G., De La Vega F.M., Briggs J., Gunther S., Prescott N.J., Onnie C.M., Hasler R., Sipos B., Folsch U.R., Lengauer T., Platzer M., Mathew C.G., Krawczak M., Schreiber S. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat. Genet. 2007, 39:207-211.
24. Olcaydu D., Harutyunyan A., Jager R., Berg T., Gisslinger B., Pabinger I., Gisslinger H., Kralovics R. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat. Genet. 2009, 41:450-454.
25. Plo I., Nakatake M., Malivert L., de Villartay J.P., Giraudier S., Villeval J.L., Wiesmuller L., Vainchenker W. JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood 2008, 112:1402-1412.
26. Remy I., Wilson I.A., Michnick S.W. Erythropoietin receptor activation by a ligand-induced conformation change. Science 1999, 283:990-993.
27. Klampfer L., Huang J., Sasazuki T., Shirasawa S., Augenlicht L. Inhibition of interferon gamma signaling by the short chain fatty acid butyrate. Mol. Cancer Res. 2003, 1:855-862.
28. Itzkowitz S.H., Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 287:G7-17.
29. Schneider B.L., Kulesz-Martin M. Destructive cycles: the role of genomic instability and adaptation in carcinogenesis. Carcinogenesis 2004, 25:2033-2044.
30. Bollrath J., Phesse T.J., von Burstin V.A., Putoczki T., Bennecke M., Bateman T., Nebelsiek T., Lundgren-May T., Canli O., Schwitalla S., Matthews V., Schmid R.M., Kirchner T., Arkan M.C., Ernst M., Greten F.R. Gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009, 15:91-102.
31. Ribeiro D.A., Grilli D.G., Salvadori D.M. Genomic instability in blood cells is able to predict the oral cancer risk: an experimental study in rats. J. Mol. Histol. 2008, 39:481-486.